BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX opened at $0.10 on Friday. The firm has a market cap of $8.11 million, a price-to-earnings ratio of -0.46 and a beta of 1.46. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The business’s 50 day moving average is $0.25 and its two-hundred day moving average is $0.49. BioLineRx has a 52-week low of $0.08 and a 52-week high of $1.44.

BioLineRx shares are scheduled to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 29th.

Institutional Trading of BioLineRx

Several institutional investors and hedge funds have recently bought and sold shares of the company. PVG Asset Management Corp acquired a new position in shares of BioLineRx in the 2nd quarter worth approximately $70,000. Atria Investments Inc lifted its stake in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC acquired a new position in BioLineRx in the second quarter worth $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.